Targeting the fetal acetylcholine receptor in rhabdomyosarcoma

Bibliography

• Huh W, Skapek S. Childhood rhabdomyosarcoma: new insight on biology and treatment. Curr Oncol Rep 2010;12:402-10
   PubMed Web of Science ®Google Scholar
• Koscielniak E, Morgan M, Treuner J. Soft tissue sarcoma in children: prognosis and management. Pediatric Drugs 2002;4:21-8
   PubMedGoogle Scholar
• Ferrari A, Sultan I, Huang TT, Soft tissue sarcoma across the age spectrum: a population-based study from the surveillance epidemiology and end results database. Pediatr Blood Cancer 2011;57(6):943-9
   PubMed Web of Science ®Google Scholar
• Saab R, Spunt SL, Skapek SX, Michael AD. Myogenesis and rhabdomyosarcoma: the jekyll and hyde of skeletal muscle. current topics in developmental biology. Academic Press 2011;197-234
   Google Scholar
• Parham DM, Ellison DA. Rhabdomyosarcomas in adults and children: an update. Arch Pathol Lab Med 2006;130:1454-65
   PubMed Web of Science ®Google Scholar
• Jothi M, Nishijo K, Keller C, Mal AK. AKT and PAX3-FKHR cooperation enforces myogenic differentiation blockade in alveolar rhabdomyosarcoma cell. Cell Cycle 2012;11:895-908
   PubMed Web of Science ®Google Scholar
• Collins CA, Gnocchi VF, White RB, Integrated functions of pax3 and pax7 in the regulation of proliferation, cell size and myogenic differentiation. PLoS One 2009;4:e4475
   PubMed Web of Science ®Google Scholar
• Calhabeu F, Hayashi S, Morgan JE, Alveolar rhabdomyosarcoma-associated proteins PAX3/FOXO1A and PAX7/FOXO1A suppress the transcriptional activity of MyoD-target genes in muscle stem cells. Oncogene 2012; [Epub ahead of print]
   Google Scholar
• Tiffin N, Williams RD, Shipley J, Pritchard-Jones K. PAX7 expression in embryonal rhabdomyosarcoma suggests an origin in muscle satellite cells. Br J Cancer 89:327-32
   Google Scholar
• Riggi N, Cironi L, Suva ML, Stamenkovic I. Sarcomas: genetics, signalling, and cellular origins. Part 1: the fellowship of TET. J Pathol 2007;213:4-20
   PubMed Web of Science ®Google Scholar
• Merlino G, Khanna C. Fishing for the origins of cancer. Genes Dev 2007;21:1275-9
   PubMed Web of Science ®Google Scholar
• Hayes-Jordan A, Andrassy R. Rhabdomyosarcoma in children. Curr Opin Pediatr 2009;21:373-8
   Google Scholar
• Stock NM, Chibon F, Nguyen Binh MB, Adult-type rhabdomyosarcoma: analysis of 57 cases with clinicopathologic description, identification of 3 morphologic patterns and prognosis. Am J Surg Pathol 2009;33:1850-9
   Web of Science ®Google Scholar
• Chibon F, Lagarde P, Salas S, Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med 2010;16:781-7
   PubMed Web of Science ®Google Scholar
• Wachtel M, Runge T, Leuschner I, Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol 2006;24:816-22
   PubMed Web of Science ®Google Scholar
• Davicioni E, Anderson MJ, Finckenstein FG, Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the children's oncology group. Am J Pathol 2009;174:550-64
   PubMed Web of Science ®Google Scholar
• Ho RH, Johnson J, Dev VG, Whitlock JA. A novel t(2;20)(q35;p12) in embryonal rhabdomyosarcoma. Cancer Genet Cytogenet 2004;151:73-7
   Google Scholar
• Meloni-Ehrig A, Smith B, Zgoda J, Translocation (2;8)(q35;q13): a recurrent abnormality in congenital embryonal rhabdomyosarcoma. Cancer Genet Cytogenet 2009;191:43-5
   Google Scholar
• Gallego Melcon S, Sanchez de Toledo Codina J. Molecular biology of rhabdomyosarcoma. Clin Transl Oncol 2007;9:415-19
   PubMedGoogle Scholar
• Rezvani G, Lui JCK, Barnes KM, Baron J. A set of imprinted genes required for normal body growth also promotes growth of rhabdomyosarcoma cells. Pediatr Res 2012;71:32-8
   Google Scholar
• Anderson J, Gordon A, McManus A, Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma. Neoplasia 1999;1:340-8
   PubMedGoogle Scholar
• Sorensen PHB, Lynch JC, Qualman SJ, PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the childrens oncology group. J Clin Oncol 2002;20:2672-9
   PubMed Web of Science ®Google Scholar
• Olguin HC, Pisconti A. Marking the tempo for myogenesis: pax7 and the regulation of muscle stem cell fate decisions. J Cell Mol Med 2012;16:1013-25
   PubMedGoogle Scholar
• Bois PRJ, Izeradjene K, Houghton PJ, FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma. J Cell Biol 2005;170:903-12
   PubMedGoogle Scholar
• Anderson J, Ramsay A, Gould S, Pritchard-Jones K. PAX3-FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma. Am J pathol 2001;159:1089-96
   Google Scholar
• Higano CS, Schellhammer PF, Small EJ, Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115:3670-9
   PubMed Web of Science ®Google Scholar
• Reimann J, Jacobson L, Vincent A, Kornblum C. Endplate destruction due to maternal antibodies in arthrogryposis multiplex congenita. Neurology 2009;73:1806-8
   Google Scholar
• Carli M, Colombatti R, Oberlin O, European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. J Clin Oncol 2004;22:4787-94
   PubMed Web of Science ®Google Scholar
• Stevens MCG, Rey A, Bouvet N, Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third Study of the International Society of Paediatric Oncology—SIOP malignant mesenchymal tumor 89. J Clin Oncol 2005;23:2618-28
   PubMed Web of Science ®Google Scholar
• Crist WM, Anderson JR, Meza JL, Intergroup rhabdomyosarcoma study-iv: results for patients with nonmetastatic disease. J Clin Oncol 2001;19:3091-102
   PubMed Web of Science ®Google Scholar
• Walterhouse D, Watson A. Optimal management strategies for rhabdomyosarcoma in children. Pediatric Drugs 2007;9:391-400
   PubMedGoogle Scholar
• Spunt SL, Smith LM, Ruymann FB, cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome. Clin Cancer Res 2004;10:6072-9
   PubMed Web of Science ®Google Scholar
• Breneman JC, Lyden E, Pappo AS, Prognostic Factors and Clinical Outcomes in Children and Adolescents With Metastatic Rhabdomyosarcoma—A Report From the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003;21:78-84
   PubMed Web of Science ®Google Scholar
• Pappo AS, Anderson JR, Crist WM, Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the intergroup rhabdomyosarcoma study group. J Clin Oncol 1999;17:3487-93
   PubMedGoogle Scholar
• Doelken R, Weigel S, Schueler F, Poor outcome of two children with relapsed state stage IV alveolar rhabdomyosarcoma after allogeneic stem cell transplantation. Pediatr Hematol Oncol 2005;22:699-703
   PubMed Web of Science ®Google Scholar
• Gattenloehner S, Dockhorn-Dworniczak B, Leuschner I, A Comparison of MyoD1 and fetal acetylcholine receptor expression in childhood tumors and normal tissues implications for the molecular diagnosis of minimal disease in rhabdomyosarcomas. J Mol Diagn 1999;1:23-31
   Google Scholar
• Albuquerque E, Pereira E, Alkondon M, Scott W. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 2009;89:73-120
   PubMed Web of Science ®Google Scholar
• Engel AG. Current status of the congenital myasthenic syndromes. Neuromuscul Disord 2012;22:99-111
   Google Scholar
• Lukas RJ, Changeux J-P, le Novere N, International union of pharmacology. xx. current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev 1999;51:397-401
   PubMed Web of Science ®Google Scholar
• Karlin A, Cox RN, Dipaola M, functional domains of the nicotinic acetylcholine receptora. Ann N Y Acad Sci 1986;463:53-69
   Google Scholar
• Vincent A, Jacobson L, Shillito P. Response to human acetylcholine receptor alpha138–199: determinant spreading initiates autoimmunity to self-antigen in rabbits. Immunol Lett 1994;39:269-75
   PubMed Web of Science ®Google Scholar
• Shyng S, Salpeter M. Effect of reinnervation on the degradation rate of junctional acetylcholine receptors synthesized in denervated skeletal muscles. J Neurosci 1990;10:3905-15
   Google Scholar
• Sanes JR, Lichtman JW. Induction, assembly, maturation and maintenance of a postsynaptic apparatus. Nat Rev Neurosci 2001;2:791-805
   PubMed Web of Science ®Google Scholar
• Ruff RL. Neurophysiology of the neuromuscular junction: overview. Ann NY Acad Sci 2003;998:1-10
   PubMedGoogle Scholar
• Takeuchi A, Takeuchi N. On the permeability of end-plate membrane during the action of transmitter. J Physiol 1960;154:52-67
   PubMed Web of Science ®Google Scholar
• Wakkach A, Poea S, Chastre E, Establishment of a human thymic myoid cell line: phenotypic and functional characteristics. Am J Pathol 1999;155:1229-40
   Google Scholar
• Marx A, Willcox N, Leite M, Thymoma and paraneoplastic myasthenia gravis. Autoimmunity 2010;43:413-27
   PubMed Web of Science ®Google Scholar
• Mehmood QU, Shaktawat SS, Parikh O. Case of rhabdomyosarcoma presenting with myasthenia gravis. J Clin Oncol 2011;29:e653-5
   Google Scholar
• Fraterman S, Khurana TS, Rubinstein NA. Identification of acetylcholine receptor subunits differentially expressed in singly and multiply innervated fibers of extraocular muscles. Invest Ophthalmol Vis Sci 2006;47:3828-34
   Google Scholar
• Gattenloehner S, Vincent A, Leuschner I, The fetal form of the acetylcholine receptor distinguishes rhabdomyosarcomas from other childhood tumors. Am J Pathol 1998;152:437-44
   Google Scholar
• Walter D, Satheesha S, Albrecht P, CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. PLoS One 2011;6:e19506
   PubMedGoogle Scholar
• Hirotsu M, Setoguchi T, Matsunoshita Y, Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells. Br J Cancer 2009;101:2030-7
   PubMed Web of Science ®Google Scholar
• Kassar-Duchossoy L, Gayraud-Morel B, Gomes D, Mrf4 determines skeletal muscle identity in Myf5:myod double-mutant mice. Nature 2004;431:466-71
   PubMed Web of Science ®Google Scholar
• Rudnicki MA, Schnegelsberg PNJ, Stead RH, MyoD or Myf-5 is required for the formation of skeletal muscle. Cell 1993;75:1351-9
   PubMed Web of Science ®Google Scholar
• Mok GF, Sweetman D. Many routes to the same destination: lessons from skeletal muscle development. Reproduction 2011;141:301-12
   PubMed Web of Science ®Google Scholar
• Dahlqvist C, Blokzijl A, Chapman G, Functional notch signaling is required for BMP4-induced inhibition of myogenic differentiation. Development 2003;130:6089-99
   PubMedGoogle Scholar
• Gilmour BP, Fanger GR, Newton C, Multiple binding sites for myogenic regulatory factors are required for expression of the acetylcholine receptor gamma-subunit gene. J Biol Chem 1991;266:19871-4
   PubMedGoogle Scholar
• Sunyer T, Merlie JP. Cell type- and differentiation-dependent expression from the mouse acetylcholine receptor alpha-subunit promoter. J Neurosci Res 1993;36:224-34
   PubMedGoogle Scholar
• Durr I, Numberger M, Berberich C, Witzemann V. Characterization of the functional role of e-box elements for the transcriptional activity of rat acetylcholine receptor epsilon-subunit and gamma-subunit gene promoters in primary muscle cell cultures. Eur J Biochem 1994;224:353-64
   PubMedGoogle Scholar
• Rota R, Ciarapica R, Giordano A, MicroRNAs in rhabdomyosarcoma: pathogenetic implications and translational potentiality. Mol Cancer 2011;10:120
   Google Scholar
• Simon DJ, Madison JM, Conery AL, The microrna miR-1 regulates a MEF-2-dependent retrograde signal at neuromuscular junctions. Cell 2008;133:903-15
   PubMedGoogle Scholar
• Christianson JC, Green WN. Regulation of nicotinic receptor expression by the ubiquitin-proteasome system. EMBO J 2004;23:4156-65
   Google Scholar
• Poea-Guyon S, Christadoss P, Le Panse R, Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis. J Immunol 2005;174:5941-9
   PubMed Web of Science ®Google Scholar
• Simon-Keller K, Moßinger K, Bohlender A-L, Variable resistance of RMS to INFgamma signaling. ISRN Oncol 2012;2012:789152
   Google Scholar
• Gattenlohner S, Marx A, Markfort B, Rhabdomyosarcoma lysis by T cells expressing a human autoantibody-based chimeric receptor targeting the fetal acetylcholine receptor cancer res. 2006;66:24-8
   Google Scholar
• Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 2001;357:2122-8
   PubMed Web of Science ®Google Scholar
• Drachman DB. Myasthenia Gravis. N Engl J Med 1994;330:1797-810
   PubMed Web of Science ®Google Scholar
• Hohlfeld R, Wekerle H, Marx A. The immunopathogenesis of myasthenia gravis. In: Engel AG, editor. Myasthenia gravis and Myasthenic disorders. Oxford University Press; New York: 2012. p. 60-89
   Google Scholar
• Giraud M, Taubert R, Vandiedonck C, An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature 2007;448:934-7
   PubMed Web of Science ®Google Scholar
• Marx A, Hohenberger P, Hoffmann H, The autoimmune regulator AIRE in thymoma biology: autoimmunity and beyond. J Thorac Oncol 2010;5:S266-72
   PubMed Web of Science ®Google Scholar
• Leite MI, Jones M, Strobel P, Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol 2007;171:893-905
   PubMedGoogle Scholar
• Shiono H, Roxanis I, Zhang W, Scenarios for autoimmunization of T and B cells in myasthenia gravis. Ann NY Acad Sci 2003;998:237-56
   PubMedGoogle Scholar
• Weinberg CB, Hall ZW. Antibodies from patients with myasthenia gravis recognize determinants unique to extrajunctional acetylcholine receptors. Proc Natl Acad Sci 1979. 76: 504-8
   Google Scholar
• Zisimopoulou P, Lagoumintzis G, Poulas K, Tzartos SJ. Antigen-specific apheresis of human anti-acetylcholine receptor autoantibodies from myasthenia gravis patients' sera using Escherichia coli-expressed receptor domains. J Neuroimmunol 2008;200:133-41
   PubMed Web of Science ®Google Scholar
• Tzartos SJ, Bitzopoulou K, Gavra I, Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera. Ann NY Acad Sci 2008;1132:291-9
   PubMed Web of Science ®Google Scholar
• Vincent A, Newland C, Beeson D, Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen. Lancet 1995;346:24-5
   PubMed Web of Science ®Google Scholar
• Monneaux F, Muller S. Epitope spreading in systemic lupus erythematosus: identification of triggering peptide sequences. Arthritis Rheum 2002;46:1430-8
   PubMed Web of Science ®Google Scholar
• Wang H-B, Shi F-D, Li H, Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol 2001;166:6430-6
   PubMed Web of Science ®Google Scholar
• MacLennan CA, Vincent A, Marx A, Preferential expression of AChR epsilon-subunit in thymomas from patients with myasthenia gravis. J Neuroimmunol 2008;201:28-32
   Google Scholar
• Curnow J, Corlett L, Willcox N, Vincent A. Presentation by myoblasts of an epitope from endogenous acetylcholine receptor indicates a potential role in the spreading of the immune response. J Neuroimmunol 2001;115:127-34
   PubMedGoogle Scholar
• Hill M, Beeson D, Moss P, Early-onset myasthenia gravis: A recurring T-cell epitope in the adult-specific acetylcholine receptor epsilon subunit presented by the susceptibility allele HLA-DR52a. Ann Neurol 1999;45:224-31
   PubMedGoogle Scholar
• Kirkwood JM, Butterfield LH, Tarhini AA, Immunotherapy of cancer in 2012. CA Cancer J Clin 2012;62(5):309-35
   PubMed Web of Science ®Google Scholar
• Pandolfi F, Cianci R, Lolli S, Strategies to overcome obstacles to successful immunotherapy of melanoma. Int J Immunopathol Pharmacol 2008;21:493-500
   PubMed Web of Science ®Google Scholar
• Chen Y-Z, Yao X-L, Tabata Y, Gene carriers and transfection systems used in the recombination of dendritic cells for effective cancer immunotherapy. Clin Dev Immunol 2008;62:565643
   Google Scholar
• Kirkwood JM, Lee S, Moschos SJ, Immunogenicity and antitumor effects of vaccination with peptide vaccine +/− granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: eastern cooperative oncology group phase II trial E1696. Clin Cancer Res 2009;15:1443-51
   PubMed Web of Science ®Google Scholar
• Hashii Y, Sato E, Ohta H, WT1 peptide immunotherapy for cancer in children and young adults. Pediatr Blood Cancer 2010;55:352-5
   Google Scholar
• Mackall CL, Rhee EH, Read EJ, A Pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res 2008;14:4850-8
   PubMed Web of Science ®Google Scholar
• Meadors JL, Cui Y, Chen Q-R, Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy. Pediat Blood Cancer 2011;57:921-9
   PubMedGoogle Scholar
• Wrzesinski C, Paulos CM, Kaiser A, increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother 2010;33:1-7
   PubMed Web of Science ®Google Scholar
• Iyer U, Kadambi VJ. Antibody drug conjugates—Trojan horses in the war on cancer. J Pharmacol Toxicol Methods 2011;64:207-12
   PubMed Web of Science ®Google Scholar
• Lorberboum-Galski H. Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases. Expert Opin Drug Deliv 2011;8:605-21
   PubMed Web of Science ®Google Scholar
• Fitzgerald DJ, Moskatel E, Ben-josef G, Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737. Leuk Lymphoma 2011;52:79-81
   PubMed Web of Science ®Google Scholar
• Litvak-Greenfeld D, Benhar I. Risks and untoward toxicities of antibody-based immunoconjugates. Adv Drug Delivery Rev
   Google Scholar
• Mathew M, Verma RS. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy. Cancer Sci 2009;100:1359-65
   PubMed Web of Science ®Google Scholar
• Matthews I, Sims G, Ledwidge S, Antibodies to acetylcholine receptor in parous women with myasthenia: evidence for immunization by fetal antigen. Lab Invest 2002;82:1407-17
   PubMedGoogle Scholar
• Barth S, Huhn M, Matthey B, Ki-4(scFv)–ETA′, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood 2000;95:3909-14
   PubMed Web of Science ®Google Scholar
• Gattenlohner S, Jorißen H, Huhn M, A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model. J Biomed Biotechnol 2010;2010:187621
   Google Scholar
• Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res 2011;17:6398-405
   PubMed Web of Science ®Google Scholar
• Onda M, Beers R, Xiang L, Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc Natl Acad Sci 2011. 108: 5742-7
   Google Scholar
• Madhumathi J, Verma RS. Therapeutic targets and recent advances in protein immunotoxins. Curr Opin Microbiol. 2011;17(3):300-9
   Google Scholar
• Moritz D, Groner B. A spacer region between the single chain antibody and the CD3zeta chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity. Gene Ther 1995;2:539-46
   PubMed Web of Science ®Google Scholar
• Aguilar LK, Guzik BW, Aguilar-Cordova E. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development. J Cell Biochem 2011;112:1969-77
   PubMed Web of Science ®Google Scholar
• Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989;7:445-80
   PubMed Web of Science ®Google Scholar
• Hombach A, Wieczarkowiecz A, Marquardt T, Tumor-Specific T Cell Activation by recombinant immunoreceptors: CD3{zeta} Signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3{zeta} signaling receptor molecule. J Immunol 2001;167:6123-31
   PubMed Web of Science ®Google Scholar
• Kowolik C, Topp M, Gonzalez S, CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006;66:10995-1004
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Hombach AA, Abken H. CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack. Gene Ther 2011;18:62-72
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Feldman SA, B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells. Blood 2011;19(12):2709-20
   Google Scholar
• Park JH, Brentjens RJ. Adoptive immunotherapy for B cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discov Med 2010;9:277-88
   PubMed Web of Science ®Google Scholar
• Landmeier S, Altvater B, Pscherer S, Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo. Leukemia 2010;24:1080-4
   PubMedGoogle Scholar
• Simon-Keller K, Paschen A, Eichmuller S, Adoptive T-zell-therapie des rhabdomyosarkoms. Pathologe 2010;31:215-20
   Google Scholar
• Fourcade J, Sun Z, Benallaoua M, Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients. J Exper Med 2010;207:2175-86
   PubMed Web of Science ®Google Scholar
• Kashkar H, Seeger J-M, Hombach A, XIAP targeting sensitizes Hodgkin lymphoma cells for cytolytic T-cell attack. Blood 2006;108:3434-40
   PubMed Web of Science ®Google Scholar
• Seeger JM, Schmidt P, Brinkmann K, The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack cancer res. 2010;70:1825-34
   Google Scholar
• Hu D, Liu S, Shi L, Cleavage of survivin by ganzyme M triggers degradation of the survivin-X-linked Inhibitor of Apoptosis Protein (XIAP) complex to free caspase activity leading to cytolysis of target tumor cells. J Biol Chem 2010;285:18326-35
   Google Scholar
• Altieri D. Survivin and IAP proteins in cell-death mechanisms. Biochem J 2010;430:199-205
   PubMed Web of Science ®Google Scholar
• Melcher A, Parato K, Rooney CM, Bell JC. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 2011;19:1008-16
   PubMed Web of Science ®Google Scholar
• Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Micro 2008;6:529-40
   PubMed Web of Science ®Google Scholar
• Nakamura T, Peng K-W, Harvey M, Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotech 2005;23:209-14
   PubMed Web of Science ®Google Scholar
• Nitzki F, Zibat A, Frommhold A, Uncommitted precursor cells might contribute to increased incidence of embryonal rhabdomyosarcoma in heterozygous Patched1-mutant mice. Oncogene 2011;30:4428-36
   Google Scholar
• Kawa S, Onda M, Ho M, The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan. MABs 2011;3:479-86
   PubMed Web of Science ®Google Scholar